(Finance) – Discount for Fennec Pharmaceuticalswhich passes from hand to loss of 10.76%.
The drug manufacturer closed the fourth quarter with a loss of $ 0.06 per action against the profit of $ 0.17 per share provided for by analysts. As for product sales, they were 7.93 million dollars lower than 16.72 billion in the consensus.
The scenario on a weekly basis of Fennec Pharmaceuticals detects a lock of the curve with respect to the force expressed by Nasdaq 100. This folding could make the title subject to sales by the operators.
Technically, Fennec Pharmaceuticals It is in a strengthening phase with resistance area seen to 6.77 USD, while the more immediate support is glimpsed at 5.63. At the operational level, a continuation of the session in the name of the bull with resistance is expected to be seen at 7.91.